Revance Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Revance Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q2 2024.
  • Revance Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$37.5M, a 44.3% increase year-over-year.
  • Revance Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$288M, a 19.6% increase year-over-year.
  • Revance Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$324M, a 9.1% increase from 2022.
  • Revance Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$356M, a 26.7% decline from 2021.
  • Revance Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$281M, a 0.28% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$288M -$37.5M +$29.8M +44.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$317M -$53.2M +$6.64M +11.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$324M -$55.7M +$90.3M +61.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$414M -$141M -$56.5M -66.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$358M -$67.3M -$5.88M -9.58% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$352M -$59.8M +$4.55M +7.07% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$356M -$146M -$82.9M -131% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$274M -$84.7M -$10.3M -13.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$263M -$61.4M +$10.8M +14.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$274M -$64.3M +$7.3M +10.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$281M -$63.1M +$15.2M +19.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$297M -$74.4M +$6.88M +8.47% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$303M -$72.2M -$11.6M -19.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$292M -$71.6M -$9.71M -15.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$282M -$78.3M -$33M -72.8% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$249M -$81.3M -$39.8M -96.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$209M -$60.6M -$23.2M -62% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$186M -$61.9M -$26.6M -75.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$159M -$45.3M -$4.71M -11.6% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-26
Q3 2019 -$155M -$41.4M -$8.58M -26.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$146M -$37.4M -$3.31M -9.71% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$143M -$35.3M -$267K -0.76% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$143M -$40.6M $0 0% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$143M -$32.8M -$2.18M -7.12% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$140M -$34.1M -$7.21M -26.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$133M -$35M -$7.88M -29% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$125M -$40.6M -$13.8M -51.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$111M -$30.7M -$12.7M -70.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$98.8M -$26.9M -$2.27M -9.24% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$96.5M -$27.2M -$7.27M -36.5% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$89.3M -$26.8M -$4.71M -21.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-02
Q3 2016 -$84.6M -$18M +$1.2M +6.24% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-02
Q2 2016 -$85.8M -$24.6M -$7.8M -46.4% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-02
Q1 2016 -$78M -$19.9M -$4.49M -29.1% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-02
Q4 2015 -$73.5M -$22.1M -$7.88M -55.5% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 -$65.6M -$19.2M -$5.2M -37.2% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 -$60.4M -$16.8M -$3.5M -26.3% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 -$56.9M -$15.4M +$6.02M +28.1% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
Q4 2014 -$62.9M -$14.2M -$4.13M -41% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-04
Q3 2014 -$58.8M -$14M -$5.1M -57.4% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-04
Q2 2014 -$53.7M -$13.3M -$1.47M -12.5% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-04
Q1 2014 -$52.2M -$21.4M +$231K +1.07% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-04
Q4 2013 -$52.4M -$10.1M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-04
Q3 2013 -$8.88M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-04
Q2 2013 -$11.8M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-04
Q1 2013 -$21.7M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.